-transparent.png){kind=logo}
Bone marrow immunoscintigraphy using a 99mTc-labelled anti-NCA-95 monoclonal antibody and conventional bone scintigraphy with 99mTc-methylene-diphosphonate were compared in the diagnosis of skeletal metastases in 58 patients with urogenital tumours. In 13 patients with metastatic disease, bone marrow immunoscintigraphy proved to be superior to bone scintigraphy, detecting 431 metastatic lesions on immunoscans as compared to 261 lesions on bone scans. However, on a patient-by-patient basis bone marrow immunoscintigraphy did not demonstrate a clinical advantage over conventional bone scanning, as in this study no patient was identified with metastatic disease still confined to the marrow space, with bone scintigraphy and bone X-ray being normal.
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
January 1993,
Acta oncologica (Stockholm, Sweden),
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
February 1999,
Nuclear medicine communications,
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
January 1995,
Der Radiologe,
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
July 1990,
Lancet (London, England),
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
January 1970,
Minerva radiologica,
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
January 1997,
Anticancer research,
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
August 1987,
RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin,
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
April 1989,
Lancet (London, England),
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
January 1996,
Clinical nuclear medicine,
G Zoeller, and
D Sandrock, and
D L Munz, and
R H Ringert
August 2007,
Der Urologe. Ausg. A,
